Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis

Sci Rep. 2018 Jan 17;8(1):998. doi: 10.1038/s41598-018-19343-9.

Abstract

Radiation-induced lung injury has restricted radiotherapy for thoracic cancer. The purpose of this study was to investigate the radioprotective effects of bromodomain and extra terminal (BET) inhibitor JQ1 in a murine model of pulmonary damage. Chest computed tomography (CT) was performed in a rat model after 20 Gy radiation of the right thorax. And histological evaluation and protein expressions of irradiated tissue were analyzed to confirm the potential anti-fibrosis effect of JQ1 and its underlying mechanisms. Moreover, colony formation assays were used to explore the effects of JQ1 on esophageal cancer Eca109 and breast cancer MCF7. JQ1 attenuated radiologic and histologic presentations of radiation-induced fibrosis, inflammatory reaction and pulmonary structural changes and the increase of Hounsfield units (HU) density and hydroxyproline content after radiation. Additionally, JQ1 suppressed BRD4, c-MYC, Collagen I, TGF-β, p-NF-κB p65, p-Smad2 and p-Smad3 expressions after irradiation, repressed proliferation and transdifferentiation of lung fibroblasts, and impaired clonogenic survival of thoracic cancer cells. Collectively, our study demonstrated for the first time that BET Bromodomain inhibitor JQ1 protected normal lung tissue after radiation, and exerted a radiosensitizing effect in thoracic cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azepines / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Collagen Type I / antagonists & inhibitors
  • Collagen Type I / genetics
  • Collagen Type I / metabolism
  • Female
  • Fibroblasts / cytology
  • Fibroblasts / drug effects*
  • Fibroblasts / metabolism
  • Fibroblasts / radiation effects
  • Gamma Rays / adverse effects*
  • Gene Expression Regulation / drug effects*
  • Gene Expression Regulation / radiation effects
  • Humans
  • Hydroxyproline / antagonists & inhibitors
  • Hydroxyproline / biosynthesis
  • Lung / metabolism
  • Lung / pathology
  • Lung / radiation effects
  • MCF-7 Cells
  • Molecular Targeted Therapy
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism
  • Proteins / antagonists & inhibitors*
  • Proteins / genetics
  • Proteins / metabolism
  • Proto-Oncogene Proteins c-myc / antagonists & inhibitors
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism
  • Pulmonary Fibrosis / etiology
  • Pulmonary Fibrosis / genetics
  • Pulmonary Fibrosis / pathology
  • Pulmonary Fibrosis / prevention & control*
  • Rats
  • Rats, Sprague-Dawley
  • Smad2 Protein / antagonists & inhibitors
  • Smad2 Protein / genetics
  • Smad2 Protein / metabolism
  • Smad3 Protein / antagonists & inhibitors
  • Smad3 Protein / genetics
  • Smad3 Protein / metabolism
  • Transcription Factors / antagonists & inhibitors
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Transforming Growth Factor beta / antagonists & inhibitors
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta / metabolism
  • Triazoles / pharmacology*

Substances

  • (+)-JQ1 compound
  • Azepines
  • Brd4 protein, rat
  • Collagen Type I
  • NF-kappa B
  • Nuclear Proteins
  • Proteins
  • Proto-Oncogene Proteins c-myc
  • Smad2 Protein
  • Smad2 protein, rat
  • Smad3 Protein
  • Smad3 protein, rat
  • Transcription Factors
  • Transforming Growth Factor beta
  • Triazoles
  • bromodomain and extra-terminal domain protein, human
  • Hydroxyproline